Fatty Liver Clinical Trial
Official title:
An Interdisciplinary Approach to the Study of Non-alcoholic Fatty Liver Disease
The purpose of this study is to evaluate how the liver receives and uses fats for energy. This will help the investigators further understand the physical and chemical processes responsible for Non-Alcoholic Fatty Liver Disease (NAFLD) in overweight females with or without NAFLD who are scheduled to undergo gastric bypass surgery.
This study involves a multidisciplinary approach that will address the metabolic mechanisms
responsible for Non-alcoholic Fatty Liver Disease (NAFLD) in humans. Nonalcoholic fatty liver
disease (NAFLD) has become an important public health problem in many industrialized
countries because of its high prevalence, potential progression to severe liver disease, and
association with cardiometabolic abnormalities, including diabetes, the metabolic syndrome,
dilated cardiomyopathy, and coronary heart disease. Although obesity is an important risk
factor for NAFLD many obese persons have minimal or no steatosis. The mechanism responsible
for the pathogenesis of steatosis is not known, but must involve one or more of the
following:
1. Increased hepatic fatty acid (FA) delivery
2. Decreased hepatic FA oxidation
3. Increased de novo lipogenesis (DNL)
4. Inadequate hepatic triglyceride secretion
We hypothesize that alterations in all of these metabolic processes are involved in the
pathogenesis of NAFLD. However, a comprehensive evaluation of these factors in individual
cohorts of subjects has never been performed, and the ability to measure hepatic FA oxidation
in vivo in human subjects has not been available.
The following Specific Aims will be evaluated in obese women with and without NAFLD, who are
scheduled for bariatric surgery:
1. Determine hepatic FA uptake and oxidation by using novel PET techniques in combination
with measurements of DNL using stable isotope tracers and by assessing liver tissue FA
oxidative capacity by evaluating gene expression of FA oxidative enzymes and
mitochondrial content.
2. Determine hepatic fatty acid delivery by using stable isotope tracers to assess the rate
of free FA (FFA) release into plasma and cellular biology methods to determine the
expression and protein content of the major tissue FA transporter (CD36).
3. Determine hepatic very-low-density lipoprotein TG (VLDL-TG) secretion rate by using
stable isotope tracers.
4. Determine liver histology and factors involved in inflammation and fibrosis by using
routine staining and immunohistochemistry.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT06051669 -
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
|
||
Not yet recruiting |
NCT05984745 -
Effect of CoQ10 on the Outcome of MAFLD Patients
|
Phase 2 | |
Completed |
NCT02565446 -
Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram
|
N/A | |
Not yet recruiting |
NCT01694342 -
Telomere Parameters in Patients With Nonalcoholic Fatty Liver
|
N/A | |
Completed |
NCT01464801 -
Resveratrol in Patients With Non-alcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT01992809 -
Omega 3 Supplementation in Fatty Liver
|
Phase 3 | |
Completed |
NCT00244569 -
Development of a Breath Test for Monitoring Patients With Liver Disease
|
Phase 3 | |
Completed |
NCT00063635 -
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
|
Phase 3 | |
Recruiting |
NCT03972319 -
Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study
|
Early Phase 1 | |
Completed |
NCT03141008 -
Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
|
||
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Recruiting |
NCT05125757 -
Lifestyle Modification in Psoriatic Patients With Fatty Liver
|
N/A | |
Recruiting |
NCT05370053 -
The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology
|
N/A | |
Recruiting |
NCT04371042 -
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
|
||
Completed |
NCT04004273 -
Diabetes, Exercise and Liver Fat (DELIVER)
|
N/A | |
Completed |
NCT02520609 -
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
|
||
Recruiting |
NCT02265276 -
A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
|
Phase 3 | |
Completed |
NCT02347007 -
Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults
|
N/A | |
Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 |